Company Monitoring Page for Clovis-Oncology

latest headlines for company on cafepharma

Clovis writes a $20 million check payable to the SEC, hoping to rid itself of the lingering roci probe
Endpoints
Thu, 08/2/18 - 11:20 pm
Tags:
Clovis Oncology, SEC, rociletinib
Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer
CP Wire
Fri, 04/6/18 - 02:46 pm
Tags:
Clovis Oncology, Rubraca, ovarian cancer
Fri, 04/6/18 - 02:41 pm
Tags:
Clovis Oncology, Rubraca, ovarian cancer
Tesaro Wants a Stronger Grip in Ovarian Cancer
Yahoo/Motley Fool
Tue, 03/27/18 - 10:10 pm
Tags:
Tesaro, AstraZeneca, Clovis Oncology, ovarian cancer, Zejula, Rubraca, Lynparza
AstraZeneca Goes Up Against 2 Cancer Upstarts
Motley Fool
Sat, 03/10/18 - 09:17 am
Tags:
AstraZeneca, Clovis Oncology, PARP inhibitors, Lynparza, ovarian cancer, breast cancer, Rubraca, Zejula
AstraZeneca's Lynparza Now 'King' Of Its Class — Triumphing Over Tesaro
Investors Business Daily
Sat, 02/3/18 - 09:09 am
Tags:
AstraZeneca, Lynparza, Tesaro, cancer, Rubraca, Clovis Oncology
Why These 3 Biotech Stocks Could Outperform Their Peers In 2018
Investors Business Daily
Sat, 01/6/18 - 12:32 pm
Tags:
biotech, Puma Biotechnology, Incyte, Clovis Oncology
3 Companies Competing to Gain Lead in Ovarian Cancer Market
Yahoo/Zacks.com
Sat, 11/25/17 - 12:35 pm
Tags:
ovarian cancer, AstraZeneca, Merck, Lynparza, Rubraca, Clovis Oncology, Zejula, Tesaro
AstraZeneca, Merck, Clovis and Tesaro, all vying for share, may all win on faster PARP growth
Fierce Pharma
Wed, 11/15/17 - 08:51 pm
Tags:
AstraZeneca, Merck, Clovis Oncology, Tesaro, PARP inhibitors, ovarian cancer, Zejula, Rubraca, Lynparza
Clovis looks to expand label for PARP inhibitor
Biopharma Dive
Wed, 10/11/17 - 10:57 pm
Tags:
Clovis Oncology, PARP inhibitors, Rubraca
AstraZeneca, Tesaro and Clovis need to slash the cost of PARP meds, watchdog says
Fierce Pharma
Mon, 10/2/17 - 10:10 pm
Tags:
AstraZeneca, Tesaro, Clovis Oncology, PARP inhibitors, drug pricing, ovarian cancer, Lynparza, Zejula, Rubraca
A Pill Might Control Pancreatic Cancer, Even If It Doesn't Cure It
Forbes
Mon, 09/11/17 - 09:16 am
Tags:
pancreatic cancer, PARP inhibitors, Clovis Oncology, Rubraca
ESMO17: Clovis seeking new indication on positive ARIEL3 data
BioPharma Dive
Sun, 09/10/17 - 11:32 am
Tags:
ESMO, Clovis Oncology, Rubraca, ovarian cancer
Here's Why Clovis Stock Is Up Almost 60% So Far in 2017
Yahoo/Zacks.com
Thu, 08/24/17 - 09:49 am
Tags:
Clovis Oncology, Rubraca, ovarian cancer
Ovarian Cancer Market Still Up For Grabs
Barron's
Sat, 08/19/17 - 10:48 am
Tags:
ovarian cancer, Lynparza, Tesaro, AstraZeneca, Clovis Oncology
Why Clovis Oncology Tumbled 13.5% Today
Motley Fool
Mon, 07/31/17 - 09:58 pm
Tags:
Clovis Oncology, Rubraca, Bristol-Myers Squibb
Bristol-Myers and Clovis will partner for cancer combination trials
Marketwatch
Mon, 07/31/17 - 10:07 am
Tags:
clinical trials, Bristol-Myers Squibb, Clovis Oncology, Opdivo, Rubraca
Cancer-fighting PARP drugs from AstraZeneca, Clovis and Tesaro largely overpriced, watchdog says
Fierce Pharma
Thu, 07/13/17 - 09:33 pm
Tags:
PARP inhibitors, AstraZeneca, Clovis Oncology, Tesaro, drug pricing
Here's Why Clovis Oncology Inc. Jumped 70% in June
Motley Fool
Fri, 07/7/17 - 08:33 am
Tags:
Clovis Oncology, ovarian cancer, Rubraca
Pfizer Fueling Growth Of Competitors' Pipelines
Forbes
Tue, 06/27/17 - 10:02 am
Tags:
Pfizer, R&D, Clovis Oncology, Puma Biotechnology, Bioventus, Shire, AstraZeneca

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.